AZ SB1720

Establishes comprehensive clozapine treatment access requirements for health insurers, requiring reimbursement for psychiatric visits at the highest complexity level without frequency restrictions and an additional 30% enhancement rate for the first 12 months of treatment.

Mandates coverage of clozapine-related services including medical weight management, specialty interventions for excessive salivation, less-invasive hematological monitoring devices, mobile phlebotomy services, genetic testing, and emergency prescription drug access outside standard refill requirements.

Requires health insurers and Arizona Health Care Cost Containment System (AHCCCS) to proactively identify underutilizing providers, provide clozapine-specific training to behavioral health providers, and establish in-home monitoring and medication delivery services for patients with serious mental illness or serious emotional disturbance designations.

Applies clozapine access and treatment protocols to county jails, state prisons, and private prison contractors for incarcerated individuals prescribed clozapine.

Mandates that inpatient behavioral health facilities with pharmacies maintain clozapine in stock and extends clozapine treatment protocol coverage to AHCCCS long-term care services and comprehensive behavioral health services for children.